

🕒 27 September 2009

GSK provides update on regulatory filings for Zunrisa/Rezonic

GlaxoSmithKline (GSK) has made the difficult decision to discontinue the regulatory filings for Zunrisa/Rezonic (casopitant), which was being developed for chemotherapy-induced and post-operative nausea and vomiting. Regulatory applications were filed in a number of countries worldwide and GSK is

HELSINN EXHIBIT 2077

Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

IPR2025-00949



currently communicating with those authorities and all study investigators.

Issued: Monday 28 September 2009, London UK

GlaxoSmithKline (GSK) has made the difficult decision to discontinue the regulatory filings for *Zunrisa/Rezonic* (casopitant), which was being developed for chemotherapy-induced and post-operative nausea and vomiting. Regulatory applications were filed in a number of countries worldwide and GSK is currently communicating with those authorities and all study investigators.

GSK has made this decision, after regulatory consultation, based on the company's assessment that significant further safety data would be required to support the registration of casopitant on a worldwide basis, which would take a considerable time to produce. Consequently, all on-going regulatory files for casopitant are being withdrawn.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com 

Enquiries:

UK Media enquiries:

Philip Thomson

(020) 8047 5502

Claire Brough

(020) 8047 5502

	Stephen Rea	(020) 8047 5502
	Alexandra Harrison	(020) 8047 5502
	Gwenan White	(020) 8047 5502
US Media enquiries:	Nancy Pekarek	(919) 483 2839
	Mary Anne Rhyne	(919) 483 2839
	Kevin Colgan	(919) 483 2839
	Lisa Behrens	(919) 483 2839
European Analyst/Investor enquiries:	David Mawdsley	(020) 8047 5564
	Sally Ferguson	(020) 8047 5543
	Gary Davies	(020) 8047 5503

	Gary Davies	(020) 8047 5503
US Analyst/ Investor enquiries:	Tom Curry	(215) 751 5419
	Jen Hill Baxter	(215) 751 7002



This is our global website, intended for visitors seeking information on GSK's worldwide business. Our market sites can be reached by visiting our location selector.

© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.

GSK plc. Registered in England and Wales No. 3888792.

Registered office: 79 New Oxford Street, London, United Kingdom. WC1A 1DG

> Modern Slavery Act Statement 2024 (PDF - 162.5KB)

GSK websites

[Locations selector](#)

[Social media directory](#)

[GSKPro for healthcare professionals](#)

[GSK study register](#)

[Supplier website](#)

[ViiV Healthcare](#)

Quick links

[Behind the Science magazine](#)

[Company](#)

[Innovation](#)

[Products](#)

[Responsibility](#)

[Investors](#)

[Media](#)

[Careers](#)

Get in touch

[Contact us](#)

[Partnerships](#)

[Report a possible side effect](#)

[GSK Speak up](#)

Follow us on:



[Accessibility](#)

[Digital sustainability](#)

[Terms of use](#)

[Cookie policy](#)

[Privacy notice](#) 

[Sitemap](#)